#influenza causes

[todayworldnews2k21]

What Is A Tripledemic? Lookout For These Three Viruses That Cause Severe Respiratory Health Issues

As the world continues to navigate post-pandemic life, new health challenges are emerging, particularly with the onset of winter. One of the rising concerns is the tripledemic, a term that has been coined to describe the simultaneous surge of three respiratory viruses—COVID-19, influenza (flu), and respiratory syncytial virus (RSV). These viruses have the potential to overwhelm healthcare systems…

[onemoreattempt]

Why is it that when I get sick I can’t ever just get a normal illness? Like I can’t just get the flu, we’ve gotta have bronchitis in there too. I can’t just have strep throat, I also need a sinus infection and an ear infection (which took 10 weeks for the medical system where I was to actually fix btw l, and during that time a medical professional told me I could get meningitis). And now, when I thought I got normal bronchitis, it turns out I have fucking pneumonia?!?!

[the-hot-zone]

got tagged by the v talented and lovely mutual @hi-raethia to have y'all vote which one of my 5 all time fav films matches my vibe best.

this one is hard bc i don't watch a lot of movies BUT i've gathered some good ones. i am tagging @glitterfreckly @lovethatlaiduslow @bookofjudith @undergroundash & @compressedconstellations

[ohello0]

Ok so…. H5N1 Bird Flu has spread to house mice in New Mexico…. a week after chicken and egg farms in Iowa plan to slaughter ~4 million contaminated chickens… and after bird flu has spread across dairy farms in 9 different states (so far)

But surely no humans have ever caught it—what was that? There have been 4 human cases in the US, 3 in this year alone (all 3 from dairy cows)? Lemme just check the CDCs summary and recommendations on bird flu real quick.. oh. Um . Clap if you’re scared

[tweedledee-and-tweedledumb]

Was anyone going to tell me that Encephalitis Lethargica was a real thing that actually did occur between 1915 and 1926 or was I just suppose to find that out on my own??

[kimtaegis]

🤒😷

[hemanthsworld]

Ultimate Guide to Respiratory Tract Infections: Symptoms, Diagnosis, and Evidence-Based Treatments for URTIs and LRTIs

Upper Respiratory Tract Infections (URTIs) Introduction Respiratory tract infections (RTIs) encompass a wide range of conditions affecting the upper and lower respiratory tracts. They are common ailments that cause significant global morbidity and economic loss. This comprehensive guide covers everything you need to know about RTIs, from symptoms and diagnosis to evidence-based treatments and…

[rival-the-rose]

Last week I went to the doctor for a pre-scheduled appointment (trying to see if putting my luxated and sub luxated ribs and shoulders back every couple weeks will train them to stay in place) and as I was going thru recent symptoms my doctor pointed out that a bunch of things I thought were random and unrelated could've in fact been a viral infection.

And it's just been rattling around my brain since then. Tiny little capsules with almost nothing but simple genetic information in them got into my body and as a side effect of making more tiny capsules, they made me barf for exactly three hours, then gave me sialoadenitis, then made my left elbow swell up and hurt. Sure. Ok. How does that help you, little capsules. Why just the left elbow, or just the sublingual salivary gland. What are you guys doing in there. I'm not mad I just wanna know

[gumjrop]

This year’s flu shot will be missing a strain of influenza it’s protected against for more than a decade.

That’s because there have been no confirmed flu cases caused by the Influenza B/Yamagata lineage since spring 2020. And the Food and Drug Administration decided this year that the strain now poses little to no threat to human health.

Scientists have concluded that widespread physical distancing and masking practiced during the early days of COVID-19 appear to have pushed B/Yamagata into oblivion.

This surprised many who study influenza, as it would be the first documented instance of a virus going extinct due to changes in human behavior, said Dr. Rebecca Wurtz, an infectious disease physician and epidemiologist at the University of Minnesota School of Public Health.

“It is such an interesting and unique story,” Wurtz said, adding that if it were not for COVID, B/Yamagata would still be circulating.

One reason COVID mitigation efforts were so effective at eliminating B/Yamagata is there was already a fair amount of immunity in the population against this strain of flu, which was also circulating at a lower level, said Dr. Kawsar Talaat, an infectious disease physician at Johns Hopkins Bloomberg School of Public Health.

In contrast, SARS-CoV-2 was a brand new virus that no one had encountered before; therefore, masking and isolation only slowed its transmission, but did not stop it.

The absence of B/Yamagata won’t change the experience of getting this year’s flu shot, which the Centers for Disease Control and Prevention recommends to everyone over 6 months old. And unvaccinated people are no less likely to get the flu, as B/Victoria and two influenza A lineages are still circulating widely and making people sick. Talaat said the disappearance of B/Yamagata doesn’t appear to have lessened the overall burden of flu, noting that the level of illness that can be attributed to any strain varies from year to year.

The CDC estimates that between 12,000 and 51,000 people die every year from influenza.

However, the manufacturing process is simplified now that the vaccine is trivalent — designed to protect against three flu viruses — instead of quadrivalent, protecting against four. That change allows more doses to be produced, said Talaat.

Ultimately, the costs of continuing to include protection against B/Yamagata in the flu shot outweigh its benefits, said Talaat.

"If you include a strain for which you don't think anybody's going to get infected into a vaccine, there are some potential risks and no potential benefits," she said. "Even though the risks might be infinitesimal, the benefits are also infinitesimal."

Scientists and public health experts have discussed for the past couple years whether to pull B/Yamagata from the flu vaccine or wait for a possible reemergence, said Kevin R. McCarthy, an assistant professor at the University of Pittsburgh's Center for Vaccine Research. But McCarthy agrees that continuing to vaccinate people against B/Yamagata does not benefit public health.

Additionally, there is a slight chance of B/Yamagata accidentally infecting the workers who manufacture the flu vaccine. The viruses, grown in eggs, are inactivated before being put into the shots: You cannot get influenza from the flu shot. But worker exposure to live B/Yamagata might occur before it's rendered harmless.

That hypothetically could lead to a reintroduction of a virus that populations have waning immunity to because B/Yamagata is no longer making people sick. While that risk is very low, McCarthy said it doesn’t make sense to produce thousands of gallons of a likely extinct virus.

It is possible that B/Yamagata continues to exist in pockets of the world that have less comprehensive flu surveillance. However, scientists aren’t worried that it is hiding in animals because humans are the only host population for B lineage flu viruses.

Scientists determined that B/Yamagata disappeared in a relatively short period of time, and this in and of itself is a success, said McCarthy. That required collaboration and data sharing from people all over the world, including countries that the U.S. has more tenuous diplomatic relationships with, like China and Russia.

“I think the fact that we can do that shows that we can get some things right,” he said.

Sarah Boden is an independent health and science journalist based in Pittsburgh.

[reasonsforhope]

"A team of researchers at Washington University in St. Louis has developed a real-time air monitor that can detect any of the SARS-CoV-2 virus variants that are present in a room in about 5 minutes.

The proof-of-concept device was created by researchers from the McKelvey School of Engineering and the School of Medicine at Washington University...

The results are contained in a July 10 publication in Nature Communications that provides details about how the technology works.

The device holds promise as a breakthrough that - when commercially available - could be used in hospitals and health care facilities, schools, congregate living quarters, and other public places to help detect not only the SARS-CoV-2 virus, but other respiratory virus aerosol such as influenza and respiratory syncytial virus (RSV) as well.

“There is nothing at the moment that tells us how safe a room is,” Cirrito said, in the university’s news release. “If you are in a room with 100 people, you don’t want to find out five days later whether you could be sick or not. The idea with this device is that you can know essentially in real time, or every 5 minutes, if there is a live virus in the air.”

How It Works

The team combined expertise in biosensing with knowhow in designing instruments that measure the toxicity of air. The resulting device is an air sampler that operates based on what’s called “wet cyclone technology.” Air is sucked into the sampler at very high speeds and is then mixed centrifugally with a fluid containing a nanobody that recognizes the spike protein from the SARS-CoV-2 virus. That fluid, which lines the walls of the sampler, creates a surface vortex that traps the virus aerosols. The wet cyclone sampler has a pump that collects the fluid and sends it to the biosensor for detection of the virus using electrochemistry.

The success of the instrument is linked to the extremely high velocity it generates - the monitor has a flow rate of about 1,000 liters per minute - allowing it to sample a much larger volume of air over a 5-minute collection period than what is possible with currently available commercial samplers. It’s also compact - about one foot wide and 10 inches tall - and lights up when a virus is detected, alerting users to increase airflow or circulation in the room.

Testing the Monitor

To test the monitor, the team placed it in the apartments of two Covid-positive patients. The real-time air samples from the bedrooms were then compared with air samples collected from a virus-free control room. The device detected the RNA of the virus in the air samples from the bedrooms but did not detect any in the control air samples.

In laboratory experiments that aerosolized SARS-CoV-2 into a room-sized chamber, the wet cyclone and biosensor were able to detect varying levels of airborne virus concentrations after only a few minutes of sampling, according to the study.

“We are starting with SARS-CoV-2, but there are plans to also measure influenza, RSV, rhinovirus and other top pathogens that routinely infect people,” Cirrito said. “In a hospital setting, the monitor could be used to measure for staph or strep, which cause all kinds of complications for patients. This could really have a major impact on people’s health.”

The Washington University team is now working to commercialize the air quality monitor."

-via Forbes, July 11, 2023

-

Holy shit. I know it's still early in the technology and more testing will inevitably be needed but holy shit.

Literally, if it bears out, this could revolutionize medicine. And maybe let immunocompromised people fucking go places again

Also, for those who don't know, Nature Communications is a very prestigious scientific journal that focuses on Pretty Big Deal research. Their review process is incredibly rigorous. This is an absolutely HUGE credibility boost to this research and prototype

[batboyblog]

Things Biden and the Democrats did, this week #25

June 28-July 5 2024

The Department of Labor's Occupational Safety and Health Administration (OSHA). Is putting forward the first ever federal safety regulation to protect worker's from excessive heat in the workplace. As climate change has caused extreme heat events to become more common work place deaths have risen from an average of 32 heat related deaths between 1992 and 2019 to 43 in 2022. The rules if finalized would require employers to provide drinking water and cool break areas at 80 degrees and at 90 degrees have mandatory 15-minute breaks every two hours and be monitored for signs of heat illness. This would effect an estimated 36 million workers.

The Federal Emergency Management Agency announced $1 Billion for 656 projects across the country aimed at helping local communities combat climate change fueled disasters like flooding and extreme heat. Some of the projects include $50 Million to Philadelphia for a stormwater pump station and combating flooding, and a grant to build Shaded bus shelters in Washington, D.C.

The Department of Transportation announced thanks to efforts by the Biden Administration flight cancellations at the lowest they've been in a decade. At just 1.4% for the year so far. Transportation Secretary Pete Buttigieg credited the Department's new rules requiring automatic refunds for any cancellations or undue delays as driving the good numbers as well as the investment of $25 billion in airport infrastructure that was in the Bipartisan Infrastructure Law.

The Department of Transportation announced $600 million in the 3rd round of funding to reconnect communities. Many communities have been divided by highways and other Infrastructure projects over the years. Most often effecting racial minority and poor areas. The Biden Administration is dedicated to addressing these injustices and helping reconnect communities split for decades. This funding round will see Atlanta’s Southside Communities reconnected as well as a redesign for Birmingham’s Black Main Street, reconnecting a community split by Interstate 65 in the 1960s. 

The Biden Administration approved its 9th offshore wind power project. About 9 miles off the coast of New Jersey the planned wind farm will generated 2,800 megawatts of electricity, enough to power almost a million homes with totally clear power. This will bring the total amount of clean wind power generated by projects approved by the Biden Administration to 13 gigawatts. The Administration's climate goal is to generate 30 gigawatts from wind.

The Biden Administration announced funding for 12 new Regional Technology and Innovation Hubs. The $504 million dollars will go to supporting tech hubs in, Colorado, Montana, Indiana, Illinois, Nevada, New York, New Hampshire, South Carolina, Florida, Ohio, Oklahoma, and Wisconsin. These tech hubs together with 31 already announced and funded will support high tech manufacturing jobs, as well as training for 21st century jobs for millions of American workers.

HHS announced over $200 million to support improved care for older Americans, particularly those with Alzheimer’s and related dementias. The money is focused on training primary care physicians, nurse practitioners, and other health care clinicians in best practices in elder and dementia care, as well as seeking to  integrate geriatric training into primary care. It also will support ways that families and other non-medical care givers can be educated to give support to aging people.

HHS announced $176 million to help support the development of a mRNA-based pandemic influenza vaccine. As part of the government's efforts to be ready before the next major pandemic it funds and supports new vaccine's to try to predict the next major pandemic. Moderna is working on an mRNA vaccine, much like the Covid-19, vaccine focused on the H5 and H7 avian influenza viruses, which experts fear could spread to humans and cause a Covid like event.

[todayworldnews2k21]

Heres How Bird Flu Can Cause You Severe Health Problems

In this article, we’ll explore how bird flu affects human health, the potential complications it can lead to, and why it remains a public health concern. Heres How Bird Flu Can Cause You Severe Health Problems Bird flu, also known as avian influenza, is primarily a viral infection that affects birds but can occasionally infect humans and other animals. While bird flu is relatively rare in…

[covid-safer-hotties]

FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants - Published Aug 22, 2024

Today, the U.S. Food and Drug Administration approved and granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent (single) component that corresponds to the Omicron variant KP.2 strain of SARS-CoV-2. The mRNA COVID-19 vaccines have been updated with this formula to more closely target currently circulating variants and provide better protection against serious consequences of COVID-19, including hospitalization and death. Today’s actions relate to updated mRNA COVID-19 vaccines manufactured by ModernaTX Inc. and Pfizer Inc.

In early June, the FDA advised manufacturers of licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 formula) should be monovalent JN.1 vaccines. Based on the further evolution of SARS-CoV-2 and a rise in cases of COVID-19, the agency subsequently determined and advised manufacturers that the preferred JN.1-lineage for the COVID-19 vaccines (2024-2025 formula) is the KP.2 strain, if feasible.

“Vaccination continues to be the cornerstone of COVID-19 prevention,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. “These updated vaccines meet the agency’s rigorous, scientific standards for safety, effectiveness, and manufacturing quality. Given waning immunity of the population from previous exposure to the virus and from prior vaccination, we strongly encourage those who are eligible to consider receiving an updated COVID-19 vaccine to provide better protection against currently circulating variants.”

The updated mRNA COVID-19 vaccines include Comirnaty and Spikevax, both of which are approved for individuals 12 years of age and older, and the Moderna COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine, both of which are authorized for emergency use for individuals 6 months through 11 years of age.

What You Need to Know

=Unvaccinated individuals 6 months through 4 years of age are eligible to receive three doses of the updated, authorized Pfizer-BioNTech COVID-19 Vaccine or two doses of the updated, authorized Moderna COVID-19 Vaccine.

=Individuals 6 months through 4 years of age who have previously been vaccinated against COVID-19 are eligible to receive one or two doses of the updated, authorized Moderna or =Pfizer-BioNTech COVID-19 vaccines (timing and number of doses to administer depends on the previous COVID-19 vaccine received).

=Individuals 5 years through 11 years of age regardless of previous vaccination are eligible to receive a single dose of the updated, authorized Moderna or Pfizer-BioNTech COVID-19 vaccines; if previously vaccinated, the dose is administered at least 2 months after the last dose of any COVID-19 vaccine.

=Individuals 12 years of age and older are eligible to receive a single dose of the updated, approved Comirnaty or the updated, approved Spikevax; if previously vaccinated, the dose is administered at least 2 months since the last dose of any COVID-19 vaccine.

=Additional doses are authorized for certain immunocompromised individuals ages 6 months through 11 years of age as described in the Moderna COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine fact sheets.

=Individuals who receive an updated mRNA COVID-19 vaccine may experience similar side effects as those reported by individuals who previously received mRNA COVID-19 vaccines and as described in the respective prescribing information or fact sheets. The updated vaccines are expected to provide protection against COVID-19 caused by the currently circulating variants. Barring the emergence of a markedly more infectious variant of SARS-CoV-2, the FDA anticipates that the composition of COVID-19 vaccines will need to be assessed annually, as occurs for seasonal influenza vaccines.

For today’s approvals and authorizations of the mRNA COVID-19 vaccines, the FDA assessed manufacturing and nonclinical data to support the change to include the 2024-2025 formula in the mRNA COVID-19 vaccines. The updated mRNA vaccines are manufactured using a similar process as previous formulas of these vaccines. The mRNA COVID-19 vaccines have been administered to hundreds of millions of people in the U.S., and the benefits of these vaccines continue to outweigh their risks.

On an ongoing basis, the FDA will review any additional COVID-19 vaccine applications submitted to the agency and take appropriate regulatory action.

The approval of Comirnaty (COVID-19 Vaccine, mRNA) (2024-2025 Formula) was granted to BioNTech Manufacturing GmbH. The EUA amendment for the Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) was issued to Pfizer Inc.

The approval of Spikevax (COVID-19 Vaccine, mRNA) (2024-2025 Formula) was granted to ModernaTX Inc. and the EUA amendment for the Moderna COVID-19 Vaccine (2024-2025 Formula) was issued to ModernaTX Inc.

[afeelgoodblog]

The Best News of Last Week

1. A branch of the flu family tree has died and won't be included in future US vaccines

A type of flu virus that used to sicken people every year hasn't been spotted anywhere on Earth since March 2020. As such, experts have advised that the apparently extinct viruses be removed from next year's flu vaccines.

The now-extinct viruses were a branch of the influenza B family tree known as the Yamagata lineage. Scientists first reported the apparent disappearance of Yamagata viruses in 2021.

2. Hospitals must obtain written consent for pelvic and similar exams, the federal government says

Hospitals must obtain written informed consent from patients before subjecting them to pelvic exams and exams of other sensitive areas — especially if an exam will be done while the patient is unconscious, the federal government said Monday.

New guidance from the U.S. Department of Health and Human Services now requires consent for breast, pelvic, prostate and rectal exams for “educational and training purposes” performed by medical students, nurse practitioners or physician assistants.

3. Germany approves new law that will allow adults to carry up to 25 grams of cannabis for their own consumption and store up to 50 grams at home.

Germany's upper house, the Bundesrat, cleared the way to partially legalize cannabis on Friday. Adults aged 18 and over will be allowed to carry up to 25 grams of cannabis for their own consumption.

4. Tick-killing pill shows promising results in human trial | Should it pan out, the pill would be a new weapon against Lyme disease.

Tarsus Pharmaceuticals is developing a pill for humans that could provide protection against the tick-borne disease for several weeks at a time. In February, the Irvine, California–based biotech company announced results from a small, early-stage trial showing that 24 hours after taking the drug, it can kill ticks on people, with the effects lasting for up to 30 days.

5. Thailand moves to legalise same-sex marriage

Thailand has taken a historic step closer to marriage equality after the lower house passed a bill giving legal recognition to same-sex marriage.

It still needs approval from the Senate and royal endorsement to become law but it is widely expected to happen by the end of 2024, making Thailand the only South East Asian country to recognise same-sex unions.

6. French Revolution: Cyclists Now Outnumber Motorists In Paris

Official measurements have found that Paris is rapidly becoming a city of transportation cyclists. In the suburbs, where public transit is less dense, transport by car was found to be the main form of mobility. But for journeys from the outskirts of Paris to the center, the number of cyclists now far exceeds the number of motorists, a huge change from just five years ago.

7. 'Miracle' operation reverses blindness in three-year-old girl giving her 'promising' future

A three year old with a genetic condition that causes blindness is doing incredibly well after unique pioneering operation to restore her sight.

The UK is the only country performing keyhole eye surgery to inject healthy copies of a gene into sufferers’ eyes. It is being used to reverse blindness in children born with a rare condition which means they can only distinguish between light and dark. And it has given little Khadijah Chaudhry, born with Leber congenital amaurosis-4, a chance at seeing properly again.

---

That's it for this week :)

This newsletter will always be free. If you liked this post you can support me with a small kofi donation here:

Buy me a coffee ❤️

Also don’t forget to reblog this post with your friends.

[milfbro]

oh it's covid

Low key. Extremely relieved. I rather have covid 10 times. I know the risks of covid but to go through dengue again??????? I'd rather die. I would RATHER DIE.

if this is dengue AGAIN while on my period AGAIN I will. Idk I will kill myself. sorry I can't think of anything funny to say

[artsandculture]

Lady Agnew of Lochnaw (1892) 🎨 John Singer Sargent 🏛️ National Galleries Scotland 📍 Edinburgh, Scotland

Sargent’s dazzling and unforgettable image of Lady Agnew is one of the most famous of his many portraits of fashionable London society. For both the artist and his sitter, the painting was an instant success, establishing Sargent’s reputation as the portrait painter of choice for the London elite and immediately transforming the newly elevated Lady Agnew into a society celebrity.

Sargent was born in Florence and spent his childhood travelling across Europe with his wealthy American parents who restlessly followed the changing social seasons. In 1874 he entered the Paris studio of the stylish French portraitist, Carolus-Duran. The young Sargent combined the flamboyant style of his teacher with his study of old masters such as Rembrandt and Velázquez but was also influenced by Monet and Impressionism. His provocative and unconventional Portrait of Madame X caused a scandal at the Paris Salon exhibition in 1884; and, when Sargent settled in London in 1886, he initially found it difficult to find clients as his bravura, continental style of painting attracted suspicion. However, his dashing technical mastery and confident manner were ideally suited for aristocratic patronage and he soon won over his critics with his elegant, flattering portraits. When his portrait of Lady Agnew was shown at the Royal Academy in 1893, one contemporary observed: ‘London is at his feet … he has had a cracking success.’

The sitter was born Gertrude Vernon and married Andrew Noel Agnew in 1889. Her husband, fifteen years her senior, was a barrister and later an MP and deputy-Lieutenant in Wigtownshire; he succeeded his father as 9th Baronet of Lochnaw in 1892, shortly before Sargent embarked on this portrait. The exact circumstances behind the commission are not known, but the Agnews may have met the artist through mutual American friends. According to notes in her husband’s diary, work on the portrait progressed swiftly, and Sargent later recalled that it was painted in just six sittings.

Lady Agnew is shown seated in a Louis XVI chair against the backdrop of a Chinese silk hanging, both of which were standard props in Sargent’s studio. She is reported to have been of frail health; she recovered slowly from a severe bout of influenza in 1890 and was apparently still convalescing and suffering from exhaustion when she sat to Sargent, which may account for her slightly ghostly pallor in the painting. Lady Agnew fixes the spectator with an intelligent, faintly amused gaze but it is her elegant white silk dress and lilac sash that threaten to steal all our attention. There are brilliant passages of painting in the highlights, reflections and coloured shadows that show Sargent at his best as a painter of surfaces and textures, the ideal artist for a gilded, polished yet ultimately superficial society.

Sargent’s image of Lady Agnew helped her to become a leading light in fashionable circles, holding lavish salons in her London home. Ironically, the high costs of this hospitality meant that she was eventually forced to sell some family pictures including this portrait which was purchased by the Scottish National Gallery in 1925.